{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T02:19:56Z","timestamp":1768097996004,"version":"3.49.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ejso.2024.108383","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T01:33:28Z","timestamp":1714700008000},"page":"108383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Outcomes of secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer progressed after prior poly (adenosine diphosphate-ribose) polymerase inhibitors: A retrospective cohort study"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0575-0519","authenticated-orcid":false,"given":"Yuxi","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9213-2988","authenticated-orcid":false,"given":"Hua","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3171-4316","authenticated-orcid":false,"given":"Yiran","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongwen","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8480-3596","authenticated-orcid":false,"given":"Guangwen","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2024.108383_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer incidence and mortality in China, 2022","author":"Han","year":"2024","journal-title":"Journal of the National Cancer Center"},{"issue":"15","key":"10.1016\/j.ejso.2024.108383_bib2","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejso.2024.108383_bib3","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41416-018-0271-y","article-title":"Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy","volume":"119","author":"Friedlander","year":"2018","journal-title":"Br J Cancer"},{"issue":"26","key":"10.1016\/j.ejso.2024.108383_bib4","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med."},{"issue":"25","key":"10.1016\/j.ejso.2024.108383_bib5","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejso.2024.108383_bib6","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejso.2024.108383_bib7","doi-asserted-by":"crossref","unstructured":"DiSilvestro, P; Banerjee, S; Colombo, N; Scambia, G; Kim, B-G; Oaknin, A; et al., Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1\/GOG 3004 Trial. J. Clin. Oncol. 2022 JCO.22.01549 10.1200\/JCO.22.01549.","DOI":"10.1200\/JCO.22.01549"},{"key":"10.1016\/j.ejso.2024.108383_bib8","article-title":"Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1\/ENGOT-ov25 trial","author":"Lorusso","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"25","key":"10.1016\/j.ejso.2024.108383_bib9","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"34","key":"10.1016\/j.ejso.2024.108383_bib10","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1200\/JCO.22.01003","article-title":"A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45)","volume":"40","author":"Monk","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejso.2024.108383_bib11","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1001\/jamaoncol.2023.2283","article-title":"Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial","volume":"9","author":"Li","year":"2023","journal-title":"JAMA Oncology"},{"issue":"6","key":"10.1016\/j.ejso.2024.108383_bib12","article-title":"First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion","volume":"5","author":"Banerjee","year":"2020","journal-title":"ESMO Open. Nov"},{"issue":"9","key":"10.1016\/j.ejso.2024.108383_bib13","doi-asserted-by":"crossref","first-page":"972","DOI":"10.6004\/jnccn.2022.0047","article-title":"NCCN Guidelines\u00ae Insights: Ovarian Cancer, Version 3.2022","volume":"20","author":"Armstrong","year":"2022","journal-title":"J Natl Compr Canc Netw."},{"key":"10.1016\/j.ejso.2024.108383_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2019-000308","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","author":"Colombo","year":"2019","journal-title":"Int J Gynecol Cancer"},{"issue":"10","key":"10.1016\/j.ejso.2024.108383_bib15","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.annonc.2022.06.011","article-title":"Efficacy of subsequent chemotherapy for patients with BRCA1\/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2\/ENGOT Ov-21 trial","volume":"33","author":"Frenel","year":"2022","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2024.108383_bib16","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease\u2020","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2024.108383_bib17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","article-title":"Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Armstrong","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"23","key":"10.1016\/j.ejso.2024.108383_bib18","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejso.2024.108383_bib19","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","article-title":"Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Shi","year":"2021","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.ejso.2024.108383_bib20","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/aogs.13361","article-title":"Survival after secondary cytoreductive surgery and chemotherapy compared with chemotherapy alone for first recurrence in patients with platinum-sensitive epithelial ovarian cancer and no residuals after primary treatment. A registry-based study","volume":"97","author":"Szczesny","year":"2018","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"4","key":"10.1016\/j.ejso.2024.108383_bib21","first-page":"215","article-title":"Should secondary cytoreduction be used in recurrent ovarian cancer?","volume":"20","author":"Westin","year":"2022","journal-title":"Clin Adv Hematol Oncol"},{"issue":"20","key":"10.1016\/j.ejso.2024.108383_bib22","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"Ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ejso.2024.108383_bib23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/SLA.0b013e3181afde41","article-title":"The accordion severity grading System of surgical complications","volume":"250","author":"Strasberg","year":"2009","journal-title":"Ann Surg"},{"issue":"8","key":"10.1016\/j.ejso.2024.108383_bib24","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann Oncol"},{"issue":"20","key":"10.1016\/j.ejso.2024.108383_bib25","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejso.2024.108383_bib26","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/COC.0000000000001024","article-title":"PARP Inhibitors in Newly Diagnosed and Recurrent Ovarian Cancer","volume":"46","author":"Giannini","year":"2023","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejso.2024.108383_bib27","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ygyno.2023.04.002","article-title":"PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients","volume":"173","author":"Gauduchon","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"15","key":"10.1016\/j.ejso.2024.108383_bib28","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1200\/JCO.21.02085","article-title":"Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis","volume":"40","author":"Baek","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2024.108383_bib29","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ygyno.2023.07.006","article-title":"Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary study","volume":"176","author":"Sia","year":"2023","journal-title":"Gynecol Oncol."},{"key":"10.1016\/j.ejso.2024.108383_bib30","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1038\/srep04026","article-title":"Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status","volume":"4","author":"Cunningham","year":"2014","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.ejso.2024.108383_bib31","doi-asserted-by":"crossref","first-page":"334.e1","DOI":"10.1016\/j.ajog.2017.05.036","article-title":"BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study","volume":"217","author":"Petrillo","year":"2017","journal-title":"Am J Obstet Gynecol. Sep"},{"issue":"21","key":"10.1016\/j.ejso.2024.108383_bib32","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2024.108383_bib33","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41416-019-0582-7","article-title":"Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation","volume":"122","author":"Wattenberg","year":"2020","journal-title":"British Journal of Cancer"},{"issue":"3","key":"10.1016\/j.ejso.2024.108383_bib34","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ygyno.2012.03.006","article-title":"BRCA1\/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer","volume":"125","author":"Dann","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2024.108383_bib35","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.clon.2009.01.006","article-title":"Platinum sensitivity in a BRCA1 mutation carrier with advanced breast cancer","volume":"21","author":"Rhiem","year":"2009","journal-title":"Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2024.108383_bib36","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","article-title":"BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma","volume":"9","author":"Lin","year":"2019","journal-title":"Cancer Discov."},{"issue":"22","key":"10.1016\/j.ejso.2024.108383_bib37","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.21.01511","article-title":"Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.ejso.2024.108383_bib38","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1200\/JCO.18.02238","article-title":"Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16\/NOVA Trial","volume":"37","author":"Del Campo","year":"2019","journal-title":"J Clin Oncol."},{"issue":"2","key":"10.1016\/j.ejso.2024.108383_bib39","doi-asserted-by":"crossref","first-page":"107950","DOI":"10.1016\/j.ejso.2024.107950","article-title":"Secondary cytoreductive surgery followed by olaparib tablets as maintenance therapy in patients with BRCA mutated recurrent ovarian cancer: A multi-center retrospective study","volume":"50","author":"Yang","year":"2024","journal-title":"Eur J Surg Oncol."},{"issue":"3","key":"10.1016\/j.ejso.2024.108383_bib40","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.3802\/jgo.2020.31.e61","article-title":"A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study","volume":"31","author":"Shi","year":"2020","journal-title":"J Gynecol Oncol."},{"issue":"6","key":"10.1016\/j.ejso.2024.108383_bib41","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1136\/ijgc-2022-003435","article-title":"Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups","volume":"32","author":"Schettino","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ejso.2024.108383_bib42","article-title":"Secondary cytoreduction surgery for recurrent epithelial ovarian cancer patients after PARPi maintenance: a multicenter, randomized, controlled clinical trial","author":"Chen","year":"2023","journal-title":"Int J Gynecol Cancer"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798324004359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798324004359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T23:55:01Z","timestamp":1719705301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798324004359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0748798324004359"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2024.108383","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer progressed after prior poly (adenosine diphosphate-ribose) polymerase inhibitors: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2024.108383","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108383"}}